- Home
- NRXS vs CLDI Comparison
NRXS vs CLDI Comparison
Compare NRXS & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- CLDI
- Stock Information
- Founded
- NRXS 2011
- CLDI 2014
- Country
- NRXS United States
- CLDI United States
- Employees
- NRXS N/A
- CLDI N/A
- Industry
- NRXS
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRXS
- CLDI Health Care
- Exchange
- NRXS Nasdaq
- CLDI Nasdaq
- Market Cap
- NRXS 25.0M
- CLDI 20.2M
- IPO Year
- NRXS 2023
- CLDI N/A
- Fundamental
- Price
- NRXS $2.43
- CLDI $1.57
- Analyst Decision
- NRXS Strong Buy
- CLDI
- Analyst Count
- NRXS 1
- CLDI 0
- Target Price
- NRXS $7.00
- CLDI N/A
- AVG Volume (30 Days)
- NRXS 52.6K
- CLDI 476.7K
- Earning Date
- NRXS 08-12-2025
- CLDI 08-08-2025
- Dividend Yield
- NRXS N/A
- CLDI N/A
- EPS Growth
- NRXS N/A
- CLDI N/A
- EPS
- NRXS N/A
- CLDI N/A
- Revenue
- NRXS $3,217,531.00
- CLDI N/A
- Revenue This Year
- NRXS $62.14
- CLDI N/A
- Revenue Next Year
- NRXS $131.87
- CLDI N/A
- P/E Ratio
- NRXS N/A
- CLDI N/A
- Revenue Growth
- NRXS 41.93
- CLDI N/A
- 52 Week Low
- NRXS $1.33
- CLDI $1.51
- 52 Week High
- NRXS $6.20
- CLDI $46.68
- Technical
- Relative Strength Index (RSI)
- NRXS 46.52
- CLDI 29.64
- Support Level
- NRXS $2.35
- CLDI $1.51
- Resistance Level
- NRXS $2.68
- CLDI $1.73
- Average True Range (ATR)
- NRXS 0.13
- CLDI 0.30
- MACD
- NRXS 0.01
- CLDI -0.03
- Stochastic Oscillator
- NRXS 41.59
- CLDI 1.66
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.